Advanz Agrees Multi-Market Omalizumab Deal With Alvotech
Gains Rights To Market Xolair Biosimilar In Europe, Canada And Australiasia
Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.
You may also be interested in...
In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars, at the same time as revealing two new pipeline assets. Meanwhile, the company has also dropped three products from an existing European partnership with Stada and has also terminated a development deal with BiosanaPharma.
Likely frontrunner Celltrion has published 24-week Phase III data for its CT-P39 biosimilar Xolair candidate, which tees up a planned biosimilar filing later this year.
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.